[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
In an open multicenter phase III trial, prophylaxis of the urinary tract with sodium 2-mercaptoethanesulfonate (Mesnum) was carried out in 242 patients treated with oxazaphosphorines for various malignant tumors. Under the protection of Mesnum 29 patients were treated with cyclophosphamide (Endoxan), 195 with ifosfamide (Holoxan) and 8 with trofosfamide (Ixoten). Other cytostatics were also used (polychemotherapy) in 92 cases. On administration of Mesnum, 7 macrohematurias reappeared, only 3 of them however with correct application, and 22 microhematurias, 12 of them with correct application. Cylindrurias were re-established in 3 patients. In Mesnum we have a compound which can control the urotoxicity ("uroprotector") of oxazaphosphorines which limits their therapeutic use.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006417:Hematuria / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010752:Phosphoramide Mustards / Q000009:adverse effects* / Q000627:therapeutic use; D013736:Testicular Neoplasms / Q000188:drug therapy
D010752:Phosphoramide Mustards; D008623:Mercaptoethanol; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide
Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen "Uroprotektor". Bericht über eine Feldstudie.